Skip to content
Catalyst

PapersPMID:30588573

Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.

Journal of nephrology2019The record ↗

  1. Finding, moderate evidencelowersSerum phosphate concentration

What moved

1 findingHow to read these marks →
  • “However, beginning from the 3rd month, the phosphorus levels of the OAC group started to become lower than that of the placebo group, and remained so until the end of the experiment (t = 3.653, P = 0.000).”
    Study
    RCT
    Duration
    12 months
    Dose studied
    0.6-1.2 g each time, three times a day, taken with food
    Population
    Adults with stage 3-4 chronic kidney disease and serum phosphorus in the normal range at entry; phase 1 of the trial, charcoal versus placebo, 12 months

Study record

Design
randomised controlled trial
Species
human
Population
Chinese patients with stage 3-4 chronic kidney disease, Qianfoshan Hospital, Shandong. Phase 1: OAC versus placebo. Phase 2: patients who developed hyperphosphatemia, randomised to OAC, calcium carbonate or lanthanum carbonate
Participants
97
Comparator
placebo
Duration
365 days
Endpoints measured
23